Intra-Cellular Therapies, Inc.
ITCI
Rang in Aktien
#1685
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aktienkurs
$131.87
Zuletzt synchronisiert: 2025-04-02
Marktkapitalisierung
$12.68B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Intra-Cellular Therapies, Inc. (ITCI)
Anzahl der ausstehenden Aktien zum December 2024: 103.13M
Laut den neuesten Finanzberichten und dem Aktienkurs von Intra-Cellular Therapies, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 103.13M. Am Ende von December 2023 hatte das Unternehmen 95.88M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Intra-Cellular Therapies, Inc. (ITCI) von 2013 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 103.13M | 0.00% |
| 2024 | 103.13M | 7.56% |
| 2023 | 95.88M | 1.95% |
| 2022 | 94.05M | 15.74% |
| 2021 | 81.25M | 15.47% |
| 2020 | 70.36M | 27.50% |
| 2019 | 55.19M | 0.87% |
| 2018 | 54.71M | 18.46% |
| 2017 | 46.18M | 6.80% |
| 2016 | 43.24M | 20.07% |
| 2015 | 36.01M | 25.69% |
| 2014 | 28.65M | 66.35% |
| 2013 | 17.22M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 2,226.49% |
IN
|
